WO2006022409A1 - Fixateur de substances dangereuses, dispositif d'application et méthode d'application dudit fixateur - Google Patents

Fixateur de substances dangereuses, dispositif d'application et méthode d'application dudit fixateur Download PDF

Info

Publication number
WO2006022409A1
WO2006022409A1 PCT/JP2005/015633 JP2005015633W WO2006022409A1 WO 2006022409 A1 WO2006022409 A1 WO 2006022409A1 JP 2005015633 W JP2005015633 W JP 2005015633W WO 2006022409 A1 WO2006022409 A1 WO 2006022409A1
Authority
WO
WIPO (PCT)
Prior art keywords
harmful substance
scavenger
substance
harmful
egg antibody
Prior art date
Application number
PCT/JP2005/015633
Other languages
English (en)
Japanese (ja)
Other versions
WO2006022409A8 (fr
Inventor
Jun-Ichiro Arai
Mitsugu Yamashita
Original Assignee
Daikin Industries, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daikin Industries, Ltd. filed Critical Daikin Industries, Ltd.
Publication of WO2006022409A1 publication Critical patent/WO2006022409A1/fr
Publication of WO2006022409A8 publication Critical patent/WO2006022409A8/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds

Definitions

  • the present invention relates to a biological surface that captures a harmful substance (20) by contact with a harmful substance (20) by being attached to a mucosal surface such as the nose or vulva, airway epithelial surface, or corneal surface.
  • the present invention relates to an adhering harmful substance trapping agent (10), and a spraying device (30) and spraying method thereof.
  • Japanese National Publication No. Hei 8-508240 discloses a method for preventing infection derived from wounds, burns or biomaterial forces in humans and animal hosts, and is based on a host defense mechanism prior to microbial attachment and biofilm formation. Disclosed is a method comprising the step of directly applying to the wound, burn or biomaterial an immunoglobulin composition in an amount sufficient to cultivate the microorganism for pre-phagocytosis in preparation for phagocytosis or sterilization. It is described that the composition of the present invention is particularly applicable to prevention of infection.
  • the present invention has been made in view of the strong point, and the object of the present invention is to capture harmful substances (20) such as viruses and the like, and to capture harmful substances that can be used easily at low cost. (1 0) and a spraying device (30) and a spraying method thereof.
  • the present invention to achieve the above object is a biological surface-attached harmful substance scavenger (10) that captures the harmful substance (20) by contact with the harmful substance (20),
  • chicken egg antibody (11) as a harmful substance-capturing component.
  • a harmful substance scavenger (10) it may be harmful by applying it to the site where the harmful substance (20) adheres or by spraying it on the surface in advance. Since the substance (20) is captured by the chicken egg antibody (11), a high preventive effect against infection by the harmful substance (20) can be obtained.
  • the harmful substance (20) can be removed by the egg antibody (11) by attaching the harmful substance capturing agent (10) to the surface of the harmful substance (20). Since it is trapped, it is possible to obtain an effect of preventing the infection after the harmful substances (20) are attached.
  • chicken egg antibody (11) is used as a harmful substance-capturing component, so that it is inexpensive and can be easily used such as coating and gauze because it is a substance attached to the surface of the living body rather than being injected.
  • the harmful substance-trapping agent (10) of the present invention may be in the form of a liquid in which the chicken egg antibody (11) is dissolved in a solvent, or in the form of a powder.
  • the particle size is 2 to 10 ⁇ m U. Inhaled viruses and other harmful substances (20) often adhere to the upper respiratory tract (40), but if the harmful substance scavenger (10) has a particle size of ⁇ ⁇ 10 m, it is the upper respiratory tract (40). Therefore, the trapping of harmful substances (20) is effectively carried out.
  • the harmful substance (20) to be captured by the harmful substance-trapping agent (10) of the present invention is, for example, bacteria, molds, winoles, and arenoregens.
  • the harmful substance-capturing agent (10) of the present invention is a liquid substance in which a chicken egg antibody (11) is dissolved in a solvent as a harmful substance-capturing component, the particle size of 2 to It contains hen egg antibody (11) as a harmful substance trapping component that can be sprayed in the form of a mist and sprayed in the case of a powder with a particle size of 2 ⁇ : LO / zm (30) It can be sprayed in the form of a mist.
  • FIG. 1 is a schematic diagram of a chicken egg antibody (11).
  • FIG. 2 is an explanatory diagram showing a method for removing harmful substances (20).
  • the harmful substance-capturing agent (10) is a liquid substance in which the chicken egg antibody (11) as a harmful substance-capturing component is dissolved in a solvent such as water.
  • This harmful substance-trapping agent (10) has a concentration of chicken egg antibody (11) of 0.01 to 23% by mass (preferably 0.5 to 8% by mass). Contains chicken egg antibody (11).
  • FIG. 1 shows a chicken egg antibody (11).
  • the chicken egg antibody (11) is a protein that specifically reacts (antigen-antibody reaction) with a specific harmful substance (20) (antigen), has a molecular size of 7-8 nm, and has a Y-shape. It has a molecular shape.
  • the pair of branches in the Y-shaped molecular form of chicken egg antibody (11) is called Fab (lla) and the trunk is called Fc (llb). Of these, the Fab (l la) part is a toxic substance (20) To capture.
  • the type of chicken egg antibody (11) corresponds to the type of harmful substance (20) that can be captured.
  • the harmful substance (20) captured by the chicken egg antibody (11) include bacteria, molds, viruses, allergens and mycoplasma.
  • Specific examples of bacteria include Gram-positive bacteria, Staphylococcus (S. aureus and Staphylococcus epidermidis), Micrococcus, Bacillus anthracis, Bacillus cereus, Bacillus subtilis, Acne, and Gram-negative. Examples include Pseudomonas aeruginosa, Serratia, Sephacia, Streptococcus pneumoniae, Legionella, and Mycobacterium tuberculosis.
  • molds examples include yeast, Aspergillus, Vesirius, and Cladosporum.
  • Viruses include varicella virus and measles virus that infect air when splashes are less than 5 ⁇ m, influenza virus, coronavirus (SAR S virus), adenovirus, mumps virus, and rubella virus that are splashes larger than 5 ⁇ m. And herpes viruses that are contact-infected.
  • allergens include pollen, mite allergen (mite digest), mold spores, and cat allergen (pet dander). Bacteria and fungi are not inactivated by chicken egg antibody (11), but they are bacteriostatic due to high adsorption effect, whereas viruses and allergens are sterilized.
  • the chicken egg antibody (11) can be produced by administering an antigen to a chick bird to produce an immunized egg, purifying the egg yolk powder power obtained by sterilizing and spray-drying the egg yolk liquid. . That is chicken Egg antibody (11) is easy and can be produced in large quantities.
  • glycerin In addition to toxic substance scavenger (10), glycerin, ethanol, polysorbate 80, sodium hydrogen phosphate, sodium dihydrogen phosphate, sodium hydroxide, hydrochloric acid, 1-menthol, no Occasional oil may be included.
  • This harmful substance-capturing agent (10) can be produced by dissolving the chicken egg antibody (11) in a solution of water or other additives dissolved in the solvent.
  • the tank of the portable spraying device (dispersing device) (30) is filled and used.
  • the spraying device (30) is for spraying a liquid harmful substance trapping agent (10) in the form of a mist in the form of droplets having a particle size of 2 to 10 m, and its type is particularly limited.
  • the type of spraying with pressurized air, the type of spraying with ultrasonic waves, the type of spraying with vibration, the type of spraying with rotation of a rotating disk, the type of spraying with static electricity It may be of any type.
  • the spraying device (30) sprays the harmful substance-trapping agent (10) in the form of droplets having a particle size of 2 to 10 m in the form of a mist onto the oral cavity, nasal cavity, eyes, or vulva.
  • the harmful substance scavenger (10) has adhered to the oral cavity, nasal cavity, eyes, or mucous membrane of the vulva, and has been invaded from harmful substances such as viruses (20) attached to the mucosa. Capture toxic substances (20).
  • harmful substances such as viruses that have entered the body (20) often adhere to the upper respiratory tract (40), but the harmful substance-trapping agent (10) injected into the oral cavity or nasal cavity has a particle size of 2-10. Because it is m, it reaches the upper airway (40) and stays there, where it traps harmful substances (20).
  • the harmful substance scavenger (10) described above is harmful when going to a place where there is a risk of being infected with harmful substances (20), for example, before getting on a train or before entering a crowd.
  • the harmful substance (20) is captured by the egg antibody (11), so that a high preventive effect against infection by the harmful substance (20) is obtained. be able to
  • the liquid harmful substance trapping agent (10) is used by being sprayed by the spray device (30), but is not particularly limited thereto, and is used as a gargle. You can also.
  • the harmful substance-capturing agent (10) is in the form of a powder having a particle diameter of 2 to 10 m and containing a chicken egg antibody (11) as a harmful substance-capturing component.
  • This harmful substance-capturing agent (10) is obtained by embedding a chicken egg antibody (11) in an excipient, a pH regulator and a tonicity agent, and the concentration of the chicken egg antibody (11) is 0.01 to 23. For example, it is one containing about 10 mg of chicken egg antibody (11) in 1 g of freeze-dried lg.
  • composition of the chicken egg antibody (11) is the same as in the first embodiment.
  • excipients include lactose, sucrose, D-manntol, D-sorbitol, denpun, pregelatinized starch, dextrin, crystalline cellulose, low-substituted hydroxypropyl cellulose, carboxymethylcellulose sodium Arabic gum, pullulan, light anhydrous caustic acid, synthetic aluminum silicate, magnesium aluminate metasilicate and the like.
  • Examples of the pH adjuster include sodium hydrogen phosphate, sodium dihydrogen phosphate, sodium hydroxide, hydrochloric acid and the like.
  • Examples of the tonicity agent include sodium chloride salt, glycerin, D-mannitol, D-sorbitol, glucose and the like.
  • the harmful substance-capturing agent (10) is prepared by weighing the egg antibody (11), excipient, pH adjusting agent, and tonicity agent, kneading them, and granulating them. It can be manufactured by sizing and mixing, and is used by being filled in a tank of a portable spraying device (30).
  • the spraying device (30) is for spraying powder that sprays a toxic substance trapping agent (10) in the form of powder with a particle size of 2 to 10 m, and its type is particularly limited is not.
  • a powdery harmful substance scavenger (10 to 10 m in diameter) is applied to the oral cavity, nasal cavity, eyes, or vulva by means of a spraying device (30).
  • a spraying device (30).
  • the harmful substance trapping agent 10 adheres to the oral cavity, nasal cavity, eyes, or mucous membrane of the vulva, and the harmful substances such as viruses (20) adhering to the mucous membrane are present. Captures harmful substances (20).
  • harmful substances such as viruses that have entered the body (20) often adhere to the upper respiratory tract (40), but the harmful substance-trapping agent (10) injected into the oral cavity or nasal cavity has a particle size power of ⁇ ⁇ Since it is 10 m, it reaches the upper airway (40) and stays there, where it traps harmful substances (20).
  • the chicken egg antibody (11) becomes active only in the presence of water, but in this case, it is activated by the water in the body.
  • the present invention provides a biological surface-attached harmful substance capturing agent (10) for capturing the harmful substance (20) by contact with the harmful substance (20), and a spraying device (30) and a spraying method thereof. Useful for.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention décrit un fixateur de substances dangereuses (10) adhérant à la surface d’un corps vivant. Ledit fixateur capture une substance dangereuse (20) par contact avec ladite substance (20). Ledit fixateur de substances dangereuses (10) contient, au titre de composant jouant le rôle de fixateur de substances dangereuses, un anticorps extrait de l’œuf de poule.
PCT/JP2005/015633 2004-08-27 2005-08-29 Fixateur de substances dangereuses, dispositif d'application et méthode d'application dudit fixateur WO2006022409A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004-247800 2004-08-27
JP2004247800A JP2006063019A (ja) 2004-08-27 2004-08-27 有害物質捕捉剤、並びに、その散布装置及び散布方法

Publications (2)

Publication Number Publication Date
WO2006022409A1 true WO2006022409A1 (fr) 2006-03-02
WO2006022409A8 WO2006022409A8 (fr) 2008-08-07

Family

ID=35967606

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/015633 WO2006022409A1 (fr) 2004-08-27 2005-08-29 Fixateur de substances dangereuses, dispositif d'application et méthode d'application dudit fixateur

Country Status (2)

Country Link
JP (1) JP2006063019A (fr)
WO (1) WO2006022409A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5732192B2 (ja) * 2009-10-14 2015-06-10 日本ゼトック株式会社 口腔用組成物

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608217A (ja) * 1983-06-29 1985-01-17 ザ・スト−ル・リサ−チ・アンド・デイベロツプメント・コ−ポレ−シヨン 皮膚防臭剤組成物
JPS62175426A (ja) * 1986-01-27 1987-08-01 Kazufumi Shimizu 抗体及びこれを有効成分とするスプレ−剤
JPH01313439A (ja) * 1988-06-13 1989-12-18 Taiyo Kagaku Co Ltd 抗ニキビ菌皮膚外用剤
JPH01313438A (ja) * 1988-06-13 1989-12-18 Taiyo Kagaku Co Ltd 抗歯周病組成物
JPH02121910A (ja) * 1988-10-28 1990-05-09 Kanebo Ltd にきび用化粧料
WO1993006862A1 (fr) * 1991-10-11 1993-04-15 Toray Industries, Inc. Composition a base d'anticorps
JPH05105635A (ja) * 1991-10-16 1993-04-27 Banyu Pharmaceut Co Ltd 抗ウイルス剤
JPH0710728A (ja) * 1993-06-28 1995-01-13 Lion Corp 口腔用組成物
JP2002212100A (ja) * 2000-12-07 2002-07-31 Pharmafoods Kenkyusho:Kk ニキビ予防及び治療用スフィンゴ脂質組成物

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608217A (ja) * 1983-06-29 1985-01-17 ザ・スト−ル・リサ−チ・アンド・デイベロツプメント・コ−ポレ−シヨン 皮膚防臭剤組成物
JPS62175426A (ja) * 1986-01-27 1987-08-01 Kazufumi Shimizu 抗体及びこれを有効成分とするスプレ−剤
JPH01313439A (ja) * 1988-06-13 1989-12-18 Taiyo Kagaku Co Ltd 抗ニキビ菌皮膚外用剤
JPH01313438A (ja) * 1988-06-13 1989-12-18 Taiyo Kagaku Co Ltd 抗歯周病組成物
JPH02121910A (ja) * 1988-10-28 1990-05-09 Kanebo Ltd にきび用化粧料
WO1993006862A1 (fr) * 1991-10-11 1993-04-15 Toray Industries, Inc. Composition a base d'anticorps
JPH05105635A (ja) * 1991-10-16 1993-04-27 Banyu Pharmaceut Co Ltd 抗ウイルス剤
JPH0710728A (ja) * 1993-06-28 1995-01-13 Lion Corp 口腔用組成物
JP2002212100A (ja) * 2000-12-07 2002-07-31 Pharmafoods Kenkyusho:Kk ニキビ予防及び治療用スフィンゴ脂質組成物

Also Published As

Publication number Publication date
WO2006022409A8 (fr) 2008-08-07
JP2006063019A (ja) 2006-03-09

Similar Documents

Publication Publication Date Title
US5897872A (en) Iodine-containing nasal moisturizing saline solution
US6171611B1 (en) Iodine-containing nasal moisturizing saline and mouthwash solutions
JP4744533B2 (ja) 噴霧乾燥高分子型コレクチン属タンパク質及びその製造方法
TR201807714T4 (tr) İnhalasyon tedavisine yönelik nebülize antibiyotikler.
EA016072B1 (ru) Применение состава соли кальция для изменения биофизических свойств слизистой оболочки
US9433637B2 (en) Method for inhibiting influenza virus infection
AU2017277897B2 (en) Microparticles comprising a sulphur-containing compound
JP2007510712A (ja) 殺菌組成物ならびにその作製方法および使用方法
WO2006022409A1 (fr) Fixateur de substances dangereuses, dispositif d'application et méthode d'application dudit fixateur
JP2012526857A (ja) 静電的に帯電した多作用性経鼻適用、製品及び方法
JP2005206547A (ja) ウイルス捕捉組成物、及びそれを吸着させたウイルス捕捉フィルター
WO2010005637A2 (fr) Application nasale polyvalente chargée électrostatiquement, et produit et méthode associés
JP4972714B2 (ja) 静電的に帯電した多作用鼻適用、製品および方法
JP4684377B2 (ja) 花粉症予防剤
JP2003116907A (ja) 外用患部保護材
JP6039670B2 (ja) 乾燥抽出物の製造方法
CN101842318A (zh) 用于治疗和预防呼吸疾病或病症的甘油磷酸钙
WO2023044132A2 (fr) Utilisation de complexes ou de compositions de chitosane pour réduire l'infiltration de facteurs environnementaux dans le cerveau
US20210299043A1 (en) Solution and method for reducing the virulence of viruses, bacteria,yeasts, or fungus
Scherließ Nasal administration of vaccines
RU2780397C2 (ru) Микрочастицы, содержащие серосодержащие соединения
Ghosh et al. Clays in the Global War Against COVID-19: Why are They Preferable Over the Conventional Weaponry?
CN113142704A (zh) 一种防疫用口罩及使用方法
US20060269577A1 (en) Allergy inhibition
JPH0212205B2 (fr)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP